


Prior Authorization Review Panel
MCO Policy Submission

A separate copy of this form must accompany each policy submitted for review.
Policies submitted without this form will not be considered for review.

Plan: AmeriHealth Caritas Pennsylvania Community HealthChoices & Keystone First Community HealthChoices		Submission Date: 4/1/2025
Policy Number: ccp.1363		Effective Date: 4/2018 Revision Date: 3/2025
Policy Name: Immune cell function assays in transplantation		
Type of Submission:		Type of Policy:
<input type="checkbox"/> New Policy	<input checked="" type="checkbox"/> Prior Authorization Policy	
<input checked="" type="checkbox"/> Revised Policy*	<input type="checkbox"/> Base Policy	
<input type="checkbox"/> Annual Review- no revisions	<input type="checkbox"/> Experimental/Investigational Policy	
	<input type="checkbox"/> Statewide PDL	
	<input type="checkbox"/> Other:	
<p>*All revisions to the policy <u>must</u> be highlighted using track changes throughout the document.</p> <p>Please provide any clarifying information for the policy below:</p>		
Name of Authorized Individual (Please type or print):		Signature of Authorized Individual:
Manni Sethi, MD, MBA, CHCQM		

Immune cell function assays in transplantation

Clinical Policy ID: CCP.1363

Recent review date: 3/2025

Next review date: 7/2026

Policy contains: Immune cell function assay; immunosuppression; graft vs host; organ transplantation.

AmeriHealth Caritas Pennsylvania Community HealthChoices has developed clinical policies to assist with making coverage determinations. AmeriHealth Caritas Pennsylvania Community HealthChoices' clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS), state regulatory agencies, the American Medical Association (AMA), medical specialty professional societies, and peer-reviewed professional literature. These clinical policies along with other sources, such as plan benefits and state and federal laws and regulatory requirements, including any state- or plan-specific definition of "medically necessary," and the specific facts of the particular situation are considered by AmeriHealth Caritas Pennsylvania Community HealthChoices on a case by case basis, when making coverage determinations. In the event of conflict between this clinical policy and plan benefits and/or state or federal laws and/or regulatory requirements, the plan benefits and/or state and federal laws and/or regulatory requirements shall control. AmeriHealth Caritas Pennsylvania Community HealthChoices' clinical policies are for informational purposes only and not intended as medical advice or to direct treatment. Physicians and other health care providers are solely responsible for the treatment decisions for their patients. AmeriHealth Caritas Pennsylvania Community HealthChoices' clinical policies are reflective of evidence-based medicine at the time of review. As medical science evolves, AmeriHealth Caritas Pennsylvania Community HealthChoices will update its clinical policies as necessary. AmeriHealth Caritas Pennsylvania Community HealthChoices' clinical policies are not guarantees of payment.

Coverage policy

See also CCP.1067 Interferon gamma release assays for tuberculosis screening.

Immune cell function assays (e.g., ImmuKnow® [Cylex, Inc. now manufactured by Viracor Eurofins Inc., Lee's Summit, Missouri] or Pleximmune® [Plexision Inc., Pittsburgh, Pennsylvania]) to predict rejection and infection in transplantation are investigational/not clinically proven and, therefore, not medically necessary.

Limitations

No limitations were identified during the writing of this policy.

Alternative covered services

Standard of care patient evaluation and management by a network transplantation health care provider.

Background

Cellular immune function is an important factor in determining risk for acute graft rejection, opportunistic infection, and cancer among immunosuppressed transplant recipients. Immune status monitoring is necessary to balance the risk of immunosuppressant therapy and drug-related toxicity. The most frequently used tools to monitor immunosuppression in transplant recipients are therapeutic drug levels in the blood, antihuman leukocyte

antigen antibody assays, and the presence of opportunistic infections, but they are often insufficient to differentiate rejection from toxicity, necessitating allograft biopsy (Bestard, 2017).

Immune cell function assays are biomarkers that quantify T-cell and B-cell alloreactivity noninvasively, which may also provide important information in the management of autoimmune diseases (Bestard, 2017). These tests may address an unmet need for a safer, more tolerable, and cost-effective approach to immunosuppression.

Pleximmune

Pleximmune is a qualitative prognostic test that measures the inflammatory response of T-cytotoxic memory lymphocytes to donor cells and reports the results as a numeric score called the immunoreactivity index (Plexision, 2020). The index is compared with a rejection-risk threshold developed from testing of more than 200 liver or intestine recipients to assign risk. The U.S. Food and Drug Administration (2014) approved Pleximmune under a Humanitarian Device Exemption for prediction of acute cellular rejection within 60 days after transplantation in patients less than 21 years old with liver or small bowel transplantation. It is intended to be used in the pre-, early-, and late-transplantation periods in conjunction with biopsy, standard clinical assessment, and other laboratory information (U.S. Food and Drug Administration, 2020).

ImmuKnow

ImmuKnow measures the adenosine triphosphate response of stimulated peripheral blood lymphocytes (CD4+ T-cells) as an index of lymphocyte activity. The measurement of CD4 activation reflects the degree of immune function (Eurofins Viracor, 2025). The U.S. Food and Drug Administration (2002) issued 510(k) approval for detection of cell-mediated immunity in solid organ transplant recipients receiving immunosuppressive therapy.

Findings

Guidelines

The American Society of Transplantation does not mention the use of the ImmuKnow immune cell function assay in its recommendations for the screening, monitoring, and reporting of infections and complications in the evaluation of recipients of organ transplantation (Humar, 2006, reaffirmed 2013). An article representing the Society's position notes the large variability in sensitivity (ability to detect early viral infection) in transplant patients; the 11 types of assays listed do not include immune cell function assay (Fishman, 2009).

Evidence review

There is insufficient evidence to support the clinical utility of ImmuKnow or Pleximmune immune cell function assays in solid organ transplantation. The best available evidence for ImmuKnow consists of one randomized control trial to guide adjustment of immunosuppressive and anti-infective agents in solid organ transplant recipients (Ravaioli, 2015) and several retrospective studies that provide mixed results. Current evidence for Pleximmune consists of validation studies and regulatory submission data. Inconsistent findings, lack of standardized methods and testing interpretation, and individual immune response characteristics limit routine clinical use of these assays in solid organ transplant recipients.

A meta-analysis of six studies determined that, for predicting infection, ImmuKnow had a sensitivity of 0.51, specificity of 0.75, a positive likelihood ratio of 1.97, a negative likelihood ratio of 0.67, and a diagnostic odds ratio of 3.56. For predicting acute rejection, the results were sensitivity of 0.51, specificity of 0.90, a positive likelihood ratio of 4.45, a negative likelihood ratio of 0.35, and a diagnostic odds ratio of 13.81. The authors concluded that the data did not support the use of the ImmuKnow assay to predict or monitor the risks of infection and acute rejection in renal transplant recipients (Wang, 2014).

A meta-analysis assessed ImmuKnow as a diagnostic tool for predicting infection (five studies) and acute rejection (five studies) in adults after liver transplantation. For predicting infection, ImmuKnow demonstrated a sensitivity of 0.84 and a specificity of 0.75. According to the diagnostic odds ratio, transplant recipients with a positive ImmuKnow result had 14.6 greater odds of having an infection than patients with a negative test result, and a positive likelihood ratio of 3.3 suggests that a positive ImmuKnow result increases the post-test probability of infection. In contrast, ImmuKnow's test performance for acute rejection could not be validated due to considerable heterogeneity across studies (Rodrigo, 2012).

A meta-analysis of nine studies in post-transplantation recipients determined that the pooled estimates for identifying infection risk were poor, with a sensitivity of 0.58, a specificity of 0.69, a positive likelihood ratio of 2.37, a negative likelihood ratio of 0.39, and a diagnostic odds ratio of 7.41. The pooled estimates for identifying risk of rejection were also fairly poor with a sensitivity of 0.43, a specificity of 0.75, a positive likelihood ratio of 1.30, a negative likelihood ratio of 0.96, and a diagnostic odds ratio of 1.19 (Ling, 2012).

A randomized controlled study of 202 liver transplant recipients compared outcomes of serial immune function testing after surgery using ImmuKnow (n = 102) and controls/standard practice (n = 100) to guide tacrolimus dosing. In the ImmuKnow group, tacrolimus doses were reduced 25% when adenosine triphosphate levels were < 130 ng/mL and increased 25% when adenosine triphosphate were > 450 ng/mL. The ImmuKnow group had longer one-year survival (95% versus 82%; $P < .01$) and fewer infections > 14 days after transplant (42.0% vs. 54.9%, $P < .05$) (Ravaioli, 2015).

A review of CD4⁺ T-cell intracellular adenosine triphosphate levels analyzed by ImmuKnow assay in 273 liver transplantation recipients suggested a potential correlation between these levels and survival, with the peak occurring in the first three months following the procedure (Qu, 2017).

In 705 pediatric patients undergoing liver transplantation, Epstein-Barr Virus infection was detected in 468 (66.4%). ImmuKnow assay testing documented a significantly lower overall immune response in infected than non-infected patients ($P < .0001$), supporting the authors' conclusion that ImmuKnow may provide guidance in reducing immunosuppressive agents in treating post-transplant lymphoproliferative disorder (Qin, 2020).

Limited studies have evaluated the diagnostic accuracy of the Pleximmune test. The sensitivity and specificity of Pleximmune for predicting acute cellular rejection were 0.84 and 0.80, respectively, in training set-validation set testing of 214 pediatric lung or intestinal transplant recipients (Ashokkumar, 2017; Sindhi, 2016).

In 2024, we deleted several individual studies that were already analyzed in the systematic reviews and meta-analyses included in this policy. We added two large retrospective studies providing conflicting results of the utility of immune cell function assays in heart transplant recipients. The first study found no association between either immune cell function assay levels or CD3 lymphocyte counts and adverse outcomes in 78 pediatric participants (Chen, 2023). In the second study of 81 cardiac transplant recipients, participants with low pre-transplant ImmuKnow levels had a lower risk of early rejection when compared with patients with moderate or high levels. The mean ImmuKnow level in the non-rejection group was the 364.9 ng/mL of adenosine triphosphate compared with 499.3 ng/mL of adenosine triphosphate in the rejection group ($P = .020$) (Maidman, 2022). No policy changes are warranted.

In 2025, we identified no newly published, relevant literature to add to the policy. No policy changes are warranted.

References

On January 23, 2025, we searched PubMed and the databases of the Cochrane Library, the U.K. National Health Services Centre for Reviews and Dissemination, the Agency for Healthcare Research and Quality, and the Centers for Medicare & Medicaid Services. Search terms were "ImmuKnow," "immune cell function assay," and

“Pleximmune.” We included the best available evidence according to established evidence hierarchies (typically systematic reviews, meta-analyses, and full economic analyses, where available) and professional guidelines based on such evidence and clinical expertise.

Ashokkumar C, Soltys K, Mazariegos G, et al. Predicting cellular rejection with a cell-based assay: Preclinical evaluation in children. *Transplantation*. 2017;101(1):131-140. Doi: 10.1097/TP.0000000000001076.

Bestard O, Cravedi P. Monitoring alloimmune response in kidney transplantation. *J Nephrol*. 2017;30(2):187-200. Doi: 10.1007/s40620-016-0320-7.

Chen JK, Salerno DM, Corbo H, et al. Immune cell function assay and t lymphocyte counts lack association with rejection or infection in pediatric heart transplant recipients. *Clinical transplantation*. 2023;37(2):e14858. Doi: 10.1111/ctr.14858.

Eurofins Viracor. ImmuKnow®. <https://www.eurofins-viracor.com/clinical/our-testing/immuknow/>. Published 2025.

Fishman JA. Transplantation microbiology: An evolving pillar of transplant care. *Am J Transplant*. 2009;9(2):249-250. Doi: 10.1111/j.1600-6143.2008.02437.x.

Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. *Am J Transplant*. 2006;6(2):262-274. Doi: 10.1111/j.1600-6143.2005.01207.x.

Ling X, Xiong J, Liang W, et al. Can immune cell function assay identify patients at risk of infection or rejection? A meta-analysis. *Transplantation*. 2012;93(7):737-743. Doi: 10.1097/TP.0b013e3182466248.

Maidman SD, Gidea C, Reyentovich A, et al. Pre-transplant immune cell function assay as a predictor of early cardiac allograft rejection. *Clin transplant*. 2022;36(7):e14745. Doi: 10.1111/ctr.14745.

Plexision. Pleximmune™. <https://plexision.com/transplant-rejection/pleximmune>. Published 2020.

Qin T, Gu X-G, Jeong S-S, et al. Impact of EBV infection and immune function assay for lymphoproliferative disorder in pediatric patients after liver transplantation: A single-center experience. *Hepatobiliary Pancreat Dis Int*. 2020;19(1):3-11. Doi: 10.1016/j.hbpd.2019.12.005.

Qu W, Zhu Z-J, Sun L-Y, Wei L, Liu Y, Zeng Z-G. Correlation between survival interval and CD4+ T-cell intracellular ATP levels in liver transplant recipients. *Transplant Proc*. 2017;49(2):316-321. Doi: 10.1016/j.transproceed.2016.11.044.

Ravaioli M, Neri F, Lazzarotto T, et al. Immunosuppression modifications based on an immune response assay: Results of a randomized, controlled trial. *Transplantation*. 2015;99(8):1625-1632. Doi: 10.1097/tp.0000000000000650.

Rodrigo E, Lopez-Hoyos M, Corral M, et al. ImmuKnow as a diagnostic tool for predicting infection and acute rejection in adult liver transplant recipients: A systematic review and meta-analysis. *Liver Transpl*. 2012;18(10):1245-1253. Doi: 10.1002/lt.23497.

Sindhi R, Ashokkumar C, Higgs BW, et al. Profile of the Pleximmune blood test for transplant rejection risk prediction. *Expert Rev Mol Diagn*. 2016;16(4):387-393. Doi: 10.1586/14737159.2016.1139455.

U.S. Food and Drug Administration. 510(k) summary. K013169. Cylex immune cell function assay. http://www.accessdata.fda.gov/cdrh_docs/pdf/K013169.pdf. Published April 2, 2002.

U.S. Food and Drug Administration. FDA executive summary for Pleximmune HDE HI 3004. <https://www.fda.gov/media/141743/download>. Published September 26, 2020.

U.S. Food and Drug Administration. Pleximmune (Plexision, Inc.) Humanitarian device exemption (HDE) database searched using product code PHK.

<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfHDE/hde.cfm?id=375577>. Published August 27, 2014.

Wang Z, Liu X, Lu P, et al. Performance of the ImmuKnow assay in differentiating infection and acute rejection after kidney transplantation: A meta-analysis. *Transplant Proc.* 2014;46(10):3343-3351. Doi: 10.1016/j.transproceed.2014.09.109.

Policy updates

2/2018: initial review date and clinical policy effective date: 4/2018

12/2019: policy references updated.

3/2021: policy references updated.

3/2022: Policy references updated.

3/2023: Policy references updated.

3/2024: Policy references updated.

3/2025: Policy references updated.

